Medical Therapy. Efficacy or Lack of Efficacy

Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia

Dandan Zhu, Mirja Krause, Tamara Yawno, Gina D. Kusuma, Renate Schwab, Mehri Barabadi, Amina S. Maleken, Siow T. Chan, Rod Hunt, David Greening, Euan M. Wallace, Rebecca LimHudson Institute of Medical Research. Monash University. La Trobe Institute for Molecular Science and La Trobe University. University of Melbourne.Australia Stem Cell Research and TherapyStem Cell Res Ther […]

Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia Read More »

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease

Yuka Hanaki, Jun Muneuchi, Junko Yamamoto, Chie Yokota, Junya Ohmura, Hiroki Ezaki, Miwa Yoshino, Ryoko Nakamura, Miho Takeichi, Yuichiro Sugitani, Ryouhei Matsuoka, Hirohito Doi, Mamie Watanabe, Yasukiko TakahashiKyushu Hospital and Japan Community Healthcare Organization. Japan Pediatric CardiologyPediatr Cardiol 2022; 43: 1131-1135DOI: 10.1007/s00246-022-02834-y AbstractHigh-flow nasal cannula (HFNC) therapy has been applied in the perioperative respiratory care for

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease Read More »

Cardiorespiratory adaptation to low-dose dexamethasone for lung disease in extremely preterm infants: A prospective echocardiographic study

Arvind Sehgal, Marcel F. Nold, Calum T. Roberts, Samuel MenahemMonash Children’s Hospital, Monash Medical Centre and Monash University. Hudson Institute of Medical Research.Australia Journal of PhysiologyJ Physiol 2022; 600: 4361-4373DOI: 10.1113/JP282973 AbstractThe cardiovascular impact of dexamethasone (Dex) is not well understood. Most data are obtained from a 6 week, high-dose regimen, and are limited to findings

Cardiorespiratory adaptation to low-dose dexamethasone for lung disease in extremely preterm infants: A prospective echocardiographic study Read More »

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis

Jun Yasuhara, Kae Watanabe, Atsuyuki Watanabe, Takuro Shirasu, Yuichi Matsuzaki, Hirofumi Watanabe, Hisato Takagi, Naokata Sumitomo, Toshiki KunoNationwide Children’s Hospital. Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine. University of Tsukuba Hospital. University of Virginia. McGill University. Medical University of South Carolina. Shizuoka Medical Center. Saitama Medical

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis Read More »

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use

Walid A. Hussain, Deborah S. Bondi, Pooja Shah, Sherwin E. Morgan, Sudhir Sriram, Michael D. SchreiberLoyola University Medical Center. University of Chicago Medicine Comer Children’s Hospital. United States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2022; 27: 284-291DOI: 10.5863/1551-6776-27.3.284 AbstractObjective: Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension in newborns,

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use Read More »

An electrochemical nitric oxide generator for in-home inhalation therapy in pulmonary artery hypertension

Yiwei Liu, Yifan Zhu, Chenyu Jiang, Zhanhao Su, Yi Yan, Bei Feng, Wen Mao, Yuyan Zhang, Xiaojian Wang, Zhuoming Xu, Hao ZhangShanghai Children’s Medical Center and Shanghai Jiao Tong University. Fuwai Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College. Ludwig Maximilian University Munich. artner site Munich Heart Alliance. Nanjing Novlead Biotechnology

An electrochemical nitric oxide generator for in-home inhalation therapy in pulmonary artery hypertension Read More »

Oral hymecromone decreases hyaluronan in human study participants

Joelle I. Rosser, Nadine Nagy, Riya Goel, Gernot Kaber, Sally Demirdjian, Jamie Saxena, Jennifer B. Bollyky, Adam R. Frymoyer, Ana E. Pacheco-Navarro, Elizabeth B. Burgener, Jayakumar Rajadas, Zhe Wang, Olga Arbach, Colleen E. Dunn, Anissa Kalinowski, Carlos E. Milla, Paul L. BollykyStanford University. UCSF School of Pharmacy. Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin

Oral hymecromone decreases hyaluronan in human study participants Read More »

Response categorization and outcomes in extremely premature infants born at 22-26 weeks gestation that received inhaled nitric oxide for hypoxic respiratory failure

Timothy J. Boly, John M. Dagle, Jonathan M. Klein, Danielle R. Rios, Patrick J. McNamara, Regan E. GiesingerUniversity of Iowa.United States Journal of PerinatologyJ Perinatol 2023; 43: 324-331DOI: 10.1038/s41372-022-01582-4 AbstractObjective: To evaluate the outcomes of extremely premature infants who received inhaled nitric oxide(iNO) for hypoxic respiratory failure(HRF).Study design: Retrospective analysis of 107 infants born 22-26 weeks gestation who

Response categorization and outcomes in extremely premature infants born at 22-26 weeks gestation that received inhaled nitric oxide for hypoxic respiratory failure Read More »

Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases

Michael L. O’Byrne, Jennifer A. Faerber, Hannah Katcoff, Jing Huang, Jonathan B. Edelson, David M. Finkelstein, Bethan Lemley, Christopher M. Janson, Catherine M. Avitabile, Andrew C. Glatz, David J. GoldbergChildren’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. United States American Heart JournalAm Heart J 2022; 243: 158-166DOI: 10.1016/j.ahj.2021.09.012 AbstractBackground: Survivors of

Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases Read More »

Use of Vasopressin as Rescue Therapy in Refractory Hypoxia and Refractory Systemic Hypotension in Term Neonates with Severe Persistent Pulmonary Hypertension-A Prospective Observational Study

Sachin Shah, Saleha Dhalait, Anurag Fursule, Jayant Khandare, Amita KaulSurya Mother & Child Superspeciality Hospital.India America Journal of PerinatologyAm J Perinatol 2022; DOI: 10.1055/a-1969-1119 AbstractObjective: Persistent pulmonary hypertension of the newborn (PPHN) is a serious cardiorespiratory problem. PPHN is frequently associated with refractory hypoxia and hypotension, and optimal management has the potential to improve important clinical outcomes

Use of Vasopressin as Rescue Therapy in Refractory Hypoxia and Refractory Systemic Hypotension in Term Neonates with Severe Persistent Pulmonary Hypertension-A Prospective Observational Study Read More »

Scroll to Top